Study of Low-Density Lipoprotein Cholesterol (LDL-C) Reduction Using Evolocumab (AMG 145) in Japanese Patients With Advanced Cardiovascular Risk
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 409 participants.
Also called NCT01953328
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 409 participants
- Sponsor
- Registry
-
NCT01953328
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT01953328. Randomized; triple masking; primary purpose treatment. Start 2013-10 (registry gives no type); primary completion 2014-06 (actual). Results posted on 2015-12-23.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study of Low-Density Lipoprotein Cholesterol (LDL-C) Reduction Using Evolocumab (AMG 145) in Japanese Patients With Advanced Cardiovascular Risk
- Acronym
- AMG145
- Condition
- Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events
- Intervention (Drug)
- Atorvastatin
- Intervention (Biological)
- Evolocumab
- Intervention (Other)
- Placebo to Evolocumab
- Lead sponsor
- Amgen
Record details
- Record id
cardio:ct-nct01953328- Content hash
34e8ccab6fa0f5a8fd60b0f4ca976d2c97a2c720f4946f925f0185f248c769ee